Qin. Yong Jie YJ; Chu. Wai Kit WK; Huang. Li L; Ng. Clara Hoi Yen CHY; Chan. Tommy Chung Yan TCY; Ca...
The study found that a drug blocking growth‑hormone‑releasing‑hormone receptors (GHRH‑R) can kill eye‑surface cells that cause a common growth on the eye called pterygium, but it does not provide any guidance for using sermorelin or other GH‑related peptides for health or performance.
Tanaka. M M; Schally. A V AV; Telegdy. G G
A study in mice found that a growth‑hormone‑releasing‑hormone blocker called MZ‑4‑71 can act like an antidepressant, and this effect depends on certain adrenaline, serotonin, and acetylcholine receptors in the brain. The work was done by injecting the drug directly into mouse brains and testing behavior, not in people.
Gaumond. Simonetta I SI; Abdin. Rama R; Costoya. Joel J; Schally. Andrew V AV; Jimenez. Joaquin J JJ
The study tested a drug called MIA-602, which blocks growth‑hormone‑releasing hormone receptors, and found it can kill certain leukemia cells in the lab and shrink tumors in mice, even when those cells are resistant to the chemotherapy drug doxorubicin. This research is focused on cancer treatment, not on improving longevity, metabolism, or performance for healthy people.
Szepeshazi. K K; Schally. A V AV; Groot. K K; Armatis. P P; Halmos. G G; Herbert. F F; Szende. B B;...
In mice with human colon cancer, drugs that block growth‑hormone‑releasing hormone (GH‑RH) slowed tumor growth by cutting the cancer cells’ production of IGF‑II, but these drugs are not the same as sermorelin and the study doesn’t give any usable advice for everyday health or performance.
Belavgeni. Alexia A; Bornstein. Stefan R SR; von Mässenhausen. Anne A; Tonnus. Wulf W; Stumpf....
The study shows that a type of adrenal cancer cell is very sensitive to a kind of cell death called ferroptosis, but the usual drug mitotane doesn't cause this. It also finds that blocking a protective enzyme (GPX4) triggers ferroptosis, and that drugs that block growth‑hormone‑releasing hormone (GHRH) can kill these cancer cells in a non‑apoptotic way. However, the research does not test sermorelin, a GHRH‑like peptide used for hormone support, and offers no direct guidance for its use.
Gan. Jinfeng J; Ke. Xiurong X; Jiang. Jiali J; Dong. Hongmei H; Yao. Zhimeng Z; Lin. Yusheng Y; Lin....
The study shows that blocking the growth hormone‑releasing hormone receptor (GHRH‑R) with a drug called MIA‑602 can slow the growth of stomach cancer cells in lab dishes and mice, by turning off a specific inflammation‑related signaling pathway. It does not involve sermorelin, which is a GHRH agonist, and it provides no guidance for everyday health‑optimization practices.
Bellyei. Szabolcs S; Schally. Andrew V AV; Zarandi. Marta M; Varga. Jozsef L JL; Vidaurre. Irving I;...
A lab study found that a synthetic molecule that blocks growth‑hormone‑releasing hormone (GHRH) can slow down the growth and spread of cancer cells grown in a dish, but it does not tell us how to use sermorelin (a GHRH‑activating peptide) for health or longevity.
Kiaris. H H; Schally. A V AV; Varga. J L JL
This mouse study tested two growth‑hormone‑releasing‑hormone (GH‑RH) blockers and found they shrank human glioblastoma tumors and helped the mice live longer, but the work used experimental drugs, not the GH‑RH agonist sermorelin that most biohackers might take.
Wang. Haibo H; Zhang. Xianyang X; Vidaurre. Irving I; Cai. Renzhi R; Sha. Wei W; Schally. Andrew V A...
The study tested two experimental drugs that block growth‑hormone‑releasing hormone (GHRH) and found they slowed the growth of lung‑cancer cells in petri dishes and in mice. These compounds are not the same as sermorelin, which is a GHRH‑activating peptide, and the work is still far from any human use.
Kahán. Z Z; Varga. J L JL; Schally. A V AV; Rékási. Z Z; Armatis. P P; Chatzistamou....
In mice with a type of human breast cancer, drugs that block growth‑ hormone‑releasing hormone (GH‑RH) made the tumors shrink or stop growing and lowered IGF‑I levels, but this study used antagonists, not the GH‑RH‑stimulating peptide sermorelin, and was done in a cancer model, not in healthy people.
Thomas. Andreas A; Walpurgis. Katja K; Tretzel. Laura L; Brinkkötter. Paul P; Fichant. Eric E;...
The paper describes a new laboratory test that can spot large peptides like sermorelin in blood and urine, mainly for anti‑doping checks. It doesn’t give any advice on how to use sermorelin, its benefits, or safe dosing – it’s purely a detection method.
Wu. Hsien-Ming HM; Chen. Liang-Hsuan LH; Schally. Andrew V AV; Huang. Hong-Yuan HY; Soong. Yung-Kuei...
The study looked at a drug that blocks growth‑hormone‑releasing hormone (GHRH) and found it makes certain cells from early pregnancy tissue die. It shows the drug triggers cell‑death pathways, but it doesn’t tell us anything useful for using sermorelin or other GHRH‑related supplements for health, performance, or longevity.
Barabutis. Nektarios N; Siejka. Agnieszka A; Schally. Andrew V AV; Block. Norman L NL; Cai. Renzhi R...
The study shows that a splice‑variant of the growth‑hormone‑releasing hormone (GHRH) receptor, called SV1, can trigger a cell‑growth signaling pathway (MAPK) in cancer cells when it binds GHRH or its synthetic versions. This is mainly a basic‑science finding about how certain tumors respond to GHRH, not about how sermorelin works in healthy people.
Bagnasco. Michela M; Tulipano. Giovanni G; Melis. Maria R MR; Argiolas. Antonio A; Cocchi. Daniela D...
The study shows that ghrelin, a stomach‑derived hormone, directly stimulates appetite when it acts in a specific brain region (the arcuate nucleus). Blocking certain appetite‑related receptors reduces this effect, and neutralizing ghrelin in the brain lowers food intake, especially over a full day.
Lescroart. O O; Roelants. I I; Mikolajczyk. T T; Bosma. P T PT; Schulz. R W RW; Kühn. E R ER; O...
The paper describes a new test to measure growth hormone in African catfish and shows that dopamine drugs raise fish GH, while a salmon hormone analogue does not affect it. It doesn’t study sermorelin or human GH, so it offers no direct tips for people looking to boost their own hormones.
Xiong. Xiao X; Ke. Xiurong X; Wang. Lu L; Yao. Zhimeng Z; Guo. Yi Y; Zhang. Xianyang X; Chen. Yuping...
Scientists discovered that a special version of the growth‑hormone‑releasing hormone receptor (called SV1) makes esophageal cancer cells grow faster when oxygen is low, and that a drug called MIA‑602 can block this effect. This finding is about cancer biology, not about using sermorelin or other GHRH‑related peptides for health or performance.
Chu. Wai Kit WK; Law. Ka Sin KS; Chan. Sun On SO; Yam. Jason Cheuk Sing JC; Chen. Li Jia LJ; Zhang....
Scientists discovered that drugs that block the growth‑hormone‑releasing hormone receptor can kill eye‑cancer cells (retinoblastoma) while leaving normal eye cells unharmed. This finding is specific to a childhood eye tumor and does not translate into any immediate health‑boosting advice for the general public.
Horváth. J E JE; Zarándi. M M; Groot. K K; Schally. A V AV
This lab study looked at how two experimental drugs that block growth‑hormone‑releasing hormone (GHRH) affect hormone release in isolated rat pituitary cells. It found that the blockers can sharply reduce growth‑hormone output, that the effect lasts longer for one compound, and that the drop in hormone comes before any change in a signaling molecule called cAMP. The results show the system is more complicated than just cAMP driving growth‑hormone release.
Siejka. A A; Ławnicka. H H; Komorowski. J J; Schally. A V AV; Stepień. T T; Krupiń...
The study shows that a growth‑hormone‑releasing‑hormone antagonist called MZ‑4‑71 can block blood‑vessel growth signals (VEGF) and slow down mouse endothelial cell proliferation in a dish. This is a basic lab finding about a compound that is not sermorelin and has no direct link to human health protocols.
Johnson. Jaime J; Silverstein. Jeffrey J; Wolters. William R WR; Shimizu. Munetaka M; Dickhoff. Walt...
The study looked at how growth hormone (GH) changes certain blood proteins (IGFBPs) in channel catfish. Different temperatures, GH injections, and water salinity altered the levels of several IGFBPs, but these findings are specific to fish and do not translate to human use of sermorelin or other GH‑related supplements.